Single dose and steady state pharmacokinetics of temocapril and temocaprilat in young and elderly hypertensive patients

British Journal of Clinical Pharmacology

Volumn 46, Issue 4, 1998, Pages 363-367

  Puchler K ^a   Sierakowski, B ^a   Roots, I ^b  

^a Sankyo Europe GmbH   (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

ACE inhibitor; Elderly; Hypertension; Pharmacokinetics; Temocapril; Temocaprilat

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; TEMOCAPRIL; TEMOCAPRILAT;

ADULT; AGED; AGING; ANTIHYPERTENSIVE THERAPY; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG INDICATION; DRUG METABOLISM; FEMALE; HUMAN; HYPERTENSION; HYPOTENSION; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STEADY STATE;

EID: 0031656584     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2125.1998.t01-1-00785.x     Document Type: Article

References (21)

1. Burris JF. The expanding role of angiotensin converting enzyme inhibitors in the management of hypertension. J Clin Pharmacol 1995; 35: 337-342.
2. The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 1987; 316: 1429-1435.
3. Pfeffer MA, Braunwald E, Moye LA, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the Survival And Ventricular Enlargement trial. The SAVE investigators. N Engl J Med 1992; 327: 669-677.
4. Parving H-H, Hommel E, Smidt UM. Protection of kidney function and decrease in albuminuria by captopril in insulin dependent diabetics with nephropathy. Br Med J 1988; 297: 1086-1091.
5. Bjoerk S, Mulec H, Johnsen SA, Norden G, Aurell M. Renal protective effect of enalapril in diabetic nephropathy. Br Med J 1992; 304: 339-343.
6. Lewis EJ, Hunsicker LG, Brain RP, Rohde ED. The effect of angiotensin-converting enzyme inhibition on diabetic nephropathy. N Engl J Med 1993; 329: 1456-1462.
7. The GISEN Group. Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. Lancet 1997; 349: 1857-1863.
8. Heel RC, Brogden RN, Speight TM, Avery GS. Captopril: a preliminary review of its pharmacological properties and therapeutic potential in hypertension. Drugs 1980; 20: 409-452.
9. Lancaster SG, Todd PA. Lisinopril. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension and congestive heart failure. Drugs 1988; 35: 646-669.
10. Gomez HJ, Cirillo Irvin JD. Enalapril: a review of human pharmacology. Drugs 1985; 30(Suppl 1): 13-24.
11. Sierakowski B, Püchler K, Witte PU, Renneisen K, Delius W. Comparison of temocapril and atenolol in the long-term treatment of mild to moderate essential hypertension. Blood Press 1997; 6: 229-234.
12. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 31.
13. Shioya H, Shimojo M, Kawahara Y. Determination of a new angiotensin-converting enzyme inhibitor (CS-622) and its active metabolite in plasma and urine by gas chromatographymass spectrometry using negative ion chemical ionisation. J Chromatogr 1989; 496: 129-135.
14. Sierakowski B, Püchler K, Witte PU, Renneisen K, Roots I. Single-dose pharmacokinetics of temocapril and temocapril diacid in subjects with varying degrees of renal impairment. Eur J Clin Pharmacol 1997; 53: 215-220.
15. Püchler K, Eckl KM, Fritsche L, et al. Pharmacokinetics of temocapril and temocaprilat after 14 once daily oral doses of temocapril in hypertensive patients with varying degrees of renal impairment. Br J Clin Pharmacol 1997; 44: 531-536.
16. Oguchi H, Miyasaka M, Koiwai T, et al. Pharmacokinetics of temocapril and enalapril in patients with various degrees of renal insufficiency. Clin Pharmacokinet 1993; 24: 421-127.
17. Ishizuka H, Konno K, Naganuma H, et al. Temocaprilat, a novel angiotensin converting enzyme inhibitor, is excreted into bile via an ATP-dependent active transporter (cMOAT) that is deficient in Eisai hyperbilirubinemic mutant rats (EHBR). J Pharmacol Exp Ther 1997; 280: 1304-1311.
18. Kaiser G, Ackermann R, Dieterle W, et al. Pharmacokinetics and pharmacodynamics of the ACE inhibitor benazepril hydrochloride in the elderly. Eur J Clin Pharmacol 1990; 38: 379-385.
19. Williams PEO, Brown AN, Rajaguru S, Walters GE, McEwen J, Durnin C. A pharmacokinetic study of cilazapril in elderly and young volunteers. Br J Clin Pharmacol 1989; 27: 211S-215S.
20. Murdoch D, McTavish D. Fosinopril. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in essential hypertension. Drugs 1992; 43: 123-140.
21. Todd PA, Heel RC. Enalapril. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in hypertension and congestive heart failure. Drugs 1986; 31: 198-248.